|
|
Article: Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Elderly Patients with Primary Sleep Maintenance Insomnia.
- Article from:
- Business Wire
- Article date:
- April 21, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO -- Somaxon Pharmaceuticals Inc., a specialty pharmaceutical company focused on developing and marketing products for the treatment of neuro-psychiatric disorders, today announced that low-dose doxepin demonstrated statistically significant results in a Phase II dose-finding study in elderly patients with primary sleep maintenance insomnia. Low-dose doxepin demonstrated efficacy in its primary endpoint, Wake Time During Sleep (WTDS) at all doses studied, 1 mg, 3 mg and 6 mg. Low-dose doxepin also demonstrated efficacy in all secondary sleep maintenance endpoints as well as patient reported outcomes. In all dose groups, there were no differences in adverse events ...